Modulation of pd-1 signaling for treatment of diseases
AssigneeWuhan University
InventorsHongbing Shu, Shu Li, Rui Liu
Life of this patent
Estimating the term…
Abstract
Provided are compositions and methods for treating cancer, infection or Parkinson's disease. An example treatment entails administration of an agent that inhibits the biological activity or expression of MARCH5 (membrane-associated ring finger 5) or SIIP2 (src homology region 2 domain-containing phosphatase-2) or increases the biological activity or expression of USP5 (ubiquitin specific peptidase 5), optionally in combination with a common gamma-chain cytokine and/or a PD-1 inhibitor or a PD-L1 inhibitor.
Claims22
A method for treating cancer or infection in a patient in need thereof, comprising administering to the patient an effective amount of an agent that inhibits the biological activity or expression of MARCH5 (membrane-associated ring finger 5) or SHP2 (src homology region 2 domain-containing phosphatase-2) or increases the biological activity or expression of USP5 (ubiquitin specific peptidase 5).
(canceled)
(canceled)
A method for preventing or treating Parkinson's disease in a patient in need thereof, comprising administering to the patient an effective amount of an agent that inhibits the biological activity or expression of MARCH5 (membrane-associated ring finger 5).
A kit or package comprising (a) an agent that inhibits the biological activity or expression of MARCH5 (membrane-associated ring finger 5) or SHP2 (src homology region 2 domain-containing phosphatase-2) or increases the biological activity or expression of USP5 (ubiquitin specific peptidase 5), and (b1) a common gamma-chain cytokine and/or (b2) a PD-1 inhibitor or a PD-L1 inhibitor.
Dependencies are inferred from the claim text.